MARKET

GALT

GALT

Galectin Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.730
+0.040
+1.08%
After Hours: 3.728 -0.002 -0.06% 16:29 09/20 EDT
OPEN
3.680
PREV CLOSE
3.690
HIGH
3.890
LOW
3.680
VOLUME
862.36K
TURNOVER
--
52 WEEK HIGH
6.85
52 WEEK LOW
2.940
MARKET CAP
211.23M
P/E (TTM)
-8.9043
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GALT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

GALT News

  • 52 Biggest Movers From Yesterday
  • Benzinga.3d ago
  • Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
  • GlobeNewswire.5d ago
  • Galectin Therapeutics, Providence Cancer Institute Receive Patent On Use Of Belapectin In Cancer Immunotherapy
  • Benzinga.5d ago
  • Galectin Therapeutics and Providence Cancer Institute nab new patent in U.S.
  • Seeking Alpha - Article.5d ago

More

Industry

Biotechnology & Medical Research
+0.62%
Pharmaceuticals & Medical Research
+0.95%

Hot Stocks

Name
Price
%Change

About GALT

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
More

Webull offers Galectin Therapeutics Inc (GALT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.